JP2008542279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542279A5 JP2008542279A5 JP2008513583A JP2008513583A JP2008542279A5 JP 2008542279 A5 JP2008542279 A5 JP 2008542279A5 JP 2008513583 A JP2008513583 A JP 2008513583A JP 2008513583 A JP2008513583 A JP 2008513583A JP 2008542279 A5 JP2008542279 A5 JP 2008542279A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidine
- carboxamide
- phenyl
- optionally substituted
- piperidyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carboxy, amino Chemical group 0.000 claims 77
- 150000001875 compounds Chemical class 0.000 claims 51
- 125000001072 heteroaryl group Chemical group 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims 15
- 125000001931 aliphatic group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 11
- 125000003107 substituted aryl group Chemical group 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 7
- AXDGFAKTACJXOG-UHFFFAOYSA-N 2-amino-6-(3-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound COC1=CC=CC(C=2N=C(N)N=C(C=2)C(N)=O)=C1 AXDGFAKTACJXOG-UHFFFAOYSA-N 0.000 claims 6
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 6
- 125000002723 alicyclic group Chemical group 0.000 claims 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 6
- 125000003435 aroyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 4
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical group C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- BQSJMENFMHEYAS-UHFFFAOYSA-N 2-(3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl)-6-phenylpyrimidine-4-carboxamide Chemical compound N=1C(N2CC3CCCCC3CC2)=NC(C(=O)N)=CC=1C1=CC=CC=C1 BQSJMENFMHEYAS-UHFFFAOYSA-N 0.000 claims 1
- SUDVGHWNUQJVOX-UHFFFAOYSA-N 2-(cyclopropylmethylamino)-n-methyl-6-phenylpyrimidine-4-carboxamide Chemical compound N=1C(C(=O)NC)=CC(C=2C=CC=CC=2)=NC=1NCC1CC1 SUDVGHWNUQJVOX-UHFFFAOYSA-N 0.000 claims 1
- LORNOIPKRRASCE-UHFFFAOYSA-N 2-(diethylamino)-6-(2,3-dimethylphenyl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2C(=C(C)C=CC=2)C)=N1 LORNOIPKRRASCE-UHFFFAOYSA-N 0.000 claims 1
- VRJWKDMJSQKPCG-UHFFFAOYSA-N 2-(diethylamino)-6-(2,5-difluorophenyl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2C(=CC=C(F)C=2)F)=N1 VRJWKDMJSQKPCG-UHFFFAOYSA-N 0.000 claims 1
- NWQZFWPAVASWTO-UHFFFAOYSA-N 2-(diethylamino)-6-(2,6-difluorophenyl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2C(=CC=CC=2F)F)=N1 NWQZFWPAVASWTO-UHFFFAOYSA-N 0.000 claims 1
- GDDCNGFCFBHKAZ-UHFFFAOYSA-N 2-(diethylamino)-6-(3-fluorophenyl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2C=C(F)C=CC=2)=N1 GDDCNGFCFBHKAZ-UHFFFAOYSA-N 0.000 claims 1
- VEUSFFXYGRZSNW-UHFFFAOYSA-N 2-(diethylamino)-6-(4-ethylsulfonylphenyl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2C=CC(=CC=2)S(=O)(=O)CC)=N1 VEUSFFXYGRZSNW-UHFFFAOYSA-N 0.000 claims 1
- DTRZTUGMPYSMHJ-UHFFFAOYSA-N 2-(diethylamino)-6-(4-propan-2-ylphenyl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2C=CC(=CC=2)C(C)C)=N1 DTRZTUGMPYSMHJ-UHFFFAOYSA-N 0.000 claims 1
- NRKSVIFSXUJLGJ-UHFFFAOYSA-N 2-(diethylamino)-6-(5-fluoro-2-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2C(=CC=C(F)C=2)OC)=N1 NRKSVIFSXUJLGJ-UHFFFAOYSA-N 0.000 claims 1
- ZFHGMJCQSJWRGV-UHFFFAOYSA-N 2-(diethylamino)-6-(5-methylthiophen-2-yl)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(N)=O)=CC(C=2SC(C)=CC=2)=N1 ZFHGMJCQSJWRGV-UHFFFAOYSA-N 0.000 claims 1
- OAXUFOBKVUIBIV-UHFFFAOYSA-N 2-(diethylamino)-n-methyl-6-phenylpyrimidine-4-carboxamide Chemical compound CCN(CC)C1=NC(C(=O)NC)=CC(C=2C=CC=CC=2)=N1 OAXUFOBKVUIBIV-UHFFFAOYSA-N 0.000 claims 1
- IMJDWBLJLUOJSX-UHFFFAOYSA-N 2-(ethylamino)-6-(3-methoxyphenyl)pyrimidine-4-carboxamide Chemical compound CCNC1=NC(C(N)=O)=CC(C=2C=C(OC)C=CC=2)=N1 IMJDWBLJLUOJSX-UHFFFAOYSA-N 0.000 claims 1
- WHMGPNKGYSREKA-UHFFFAOYSA-N 2-[4-(4-chlorobenzoyl)piperidin-1-yl]-6-phenylpyrimidine-4-carboxamide Chemical compound N=1C(C(=O)N)=CC(C=2C=CC=CC=2)=NC=1N(CC1)CCC1C(=O)C1=CC=C(Cl)C=C1 WHMGPNKGYSREKA-UHFFFAOYSA-N 0.000 claims 1
- OMDOKCWGQXQJAH-UHFFFAOYSA-N 2-[benzyl(ethyl)amino]-6-phenylpyrimidine-4-carboxamide Chemical compound N=1C(C(N)=O)=CC(C=2C=CC=CC=2)=NC=1N(CC)CC1=CC=CC=C1 OMDOKCWGQXQJAH-UHFFFAOYSA-N 0.000 claims 1
- NESAKYGLILEUHQ-UHFFFAOYSA-N 2-[bis(2-ethoxyethyl)amino]-6-phenylpyrimidine-4-carboxamide Chemical compound CCOCCN(CCOCC)C1=NC(C(N)=O)=CC(C=2C=CC=CC=2)=N1 NESAKYGLILEUHQ-UHFFFAOYSA-N 0.000 claims 1
- HVNWWWXFJGKMBO-UHFFFAOYSA-N 2-[butyl(2-hydroxyethyl)amino]-6-phenylpyrimidine-4-carboxamide Chemical compound CCCCN(CCO)C1=NC(C(N)=O)=CC(C=2C=CC=CC=2)=N1 HVNWWWXFJGKMBO-UHFFFAOYSA-N 0.000 claims 1
- KPMHGGYESQQHMM-UHFFFAOYSA-N 2-[butyl(cyanomethyl)amino]-6-phenylpyrimidine-4-carboxamide Chemical compound CCCCN(CC#N)C1=NC(C(N)=O)=CC(C=2C=CC=CC=2)=N1 KPMHGGYESQQHMM-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- VVLKNPIRSIWVOO-UHFFFAOYSA-N 6-phenyl-2-(4-propylpiperidin-1-yl)pyrimidine-4-carboxamide Chemical compound C1CC(CCC)CCN1C1=NC(C(N)=O)=CC(C=2C=CC=CC=2)=N1 VVLKNPIRSIWVOO-UHFFFAOYSA-N 0.000 claims 1
- FUYNLSIOABLYHR-UHFFFAOYSA-N 6-phenyl-2-pyrrolidin-1-ylpyrimidine-4-carboxamide Chemical compound N=1C(C(=O)N)=CC(C=2C=CC=CC=2)=NC=1N1CCCC1 FUYNLSIOABLYHR-UHFFFAOYSA-N 0.000 claims 1
- JEYPBSQMDUFGGB-UHFFFAOYSA-N C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=CC(=CC=C1)OCC)CC.C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=C(C=CC=C1OC)OC)CC Chemical compound C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=CC(=CC=C1)OCC)CC.C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=C(C=CC=C1OC)OC)CC JEYPBSQMDUFGGB-UHFFFAOYSA-N 0.000 claims 1
- WJESGGAGDMJBBM-UHFFFAOYSA-N C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1)C.C1(CC1)CN(C1=NC(=CC(=N1)C(=O)N(C)C)C1=CC=CC=C1)CCC Chemical compound C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1)C.C1(CC1)CN(C1=NC(=CC(=N1)C(=O)N(C)C)C1=CC=CC=C1)CCC WJESGGAGDMJBBM-UHFFFAOYSA-N 0.000 claims 1
- OEEOVFNIQFXDED-UHFFFAOYSA-N C1(=CC=CC=C1)C1=CC(=NC(=N1)N1CSCC1)C(=O)N.C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=C(C=CC=C1)OC)CCO Chemical compound C1(=CC=CC=C1)C1=CC(=NC(=N1)N1CSCC1)C(=O)N.C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=C(C=CC=C1)OC)CCO OEEOVFNIQFXDED-UHFFFAOYSA-N 0.000 claims 1
- IEAQSEBNYYBMSQ-UHFFFAOYSA-N C1(=CC=CC=C1)C1=CC(=NC(=N1)NCC#C)C(=O)N.C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=C(C=C(C=C1)OC)OC)CC.C(CCCCC)N(C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1)C Chemical compound C1(=CC=CC=C1)C1=CC(=NC(=N1)NCC#C)C(=O)N.C(C)N(C1=NC(=CC(=N1)C(=O)N)C1=C(C=C(C=C1)OC)OC)CC.C(CCCCC)N(C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1)C IEAQSEBNYYBMSQ-UHFFFAOYSA-N 0.000 claims 1
- PXQMUYLHHUDPTG-UHFFFAOYSA-N C1(CC1)CN(C1=NC(=CC(=N1)C(=O)N)C1=CC(=CC=C1)OC)CCC.N1(CC=CC1)C(=O)C1=NC(=NC(=C1)C1=CC=CC=C1)N1CC=CC1 Chemical compound C1(CC1)CN(C1=NC(=CC(=N1)C(=O)N)C1=CC(=CC=C1)OC)CCC.N1(CC=CC1)C(=O)C1=NC(=NC(=C1)C1=CC=CC=C1)N1CC=CC1 PXQMUYLHHUDPTG-UHFFFAOYSA-N 0.000 claims 1
- LNRGVTZSROMRLS-UHFFFAOYSA-N CC1CN(CC(C1)C)C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1.N1(CCC1)C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1.CC1CN(CCC1)C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1 Chemical compound CC1CN(CC(C1)C)C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1.N1(CCC1)C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1.CC1CN(CCC1)C1=NC(=CC(=N1)C(=O)N)C1=CC=CC=C1 LNRGVTZSROMRLS-UHFFFAOYSA-N 0.000 claims 1
- 241000065675 Cyclops Species 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 0 *N(*=C)c1nc(/C2=C\C=C\C=C\C=C2)cc(C(N(*)O)=O)n1 Chemical compound *N(*=C)c1nc(/C2=C\C=C\C=C\C=C2)cc(C(N(*)O)=O)n1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68398205P | 2005-05-24 | 2005-05-24 | |
| US60/683,982 | 2005-05-24 | ||
| PCT/US2006/019712 WO2006127588A2 (en) | 2005-05-24 | 2006-05-22 | Modulators of atp-binding cassette transporters |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012229668A Division JP2013010800A (ja) | 2005-05-24 | 2012-10-17 | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008542279A JP2008542279A (ja) | 2008-11-27 |
| JP2008542279A5 true JP2008542279A5 (https=) | 2009-07-02 |
| JP5426878B2 JP5426878B2 (ja) | 2014-02-26 |
Family
ID=37452684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513583A Expired - Fee Related JP5426878B2 (ja) | 2005-05-24 | 2006-05-22 | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
| JP2012229668A Withdrawn JP2013010800A (ja) | 2005-05-24 | 2012-10-17 | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012229668A Withdrawn JP2013010800A (ja) | 2005-05-24 | 2012-10-17 | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8822451B2 (https=) |
| EP (1) | EP1891018B1 (https=) |
| JP (2) | JP5426878B2 (https=) |
| CN (1) | CN101223146A (https=) |
| AT (1) | ATE533749T1 (https=) |
| AU (1) | AU2006251624A1 (https=) |
| CA (1) | CA2609392A1 (https=) |
| WO (1) | WO2006127588A2 (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006111093A (ru) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
| CN101675928A (zh) * | 2003-11-14 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑 |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| US7999113B2 (en) | 2005-08-11 | 2011-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| AU2006331565A1 (en) * | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in CFTR assays and methods therewith |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CA2856037C (en) | 2005-12-28 | 2017-03-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| EP2674428B1 (en) | 2006-04-07 | 2016-04-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| DE602008005140D1 (de) | 2007-05-07 | 2011-04-07 | Novartis Ag | Organische verbindungen |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| US8450327B2 (en) | 2007-10-18 | 2013-05-28 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
| SI2578571T1 (sl) | 2007-11-16 | 2016-01-29 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto |
| CA2705405A1 (en) * | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | New compounds |
| EP3683218B1 (en) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| MX365732B (es) * | 2007-12-07 | 2019-06-12 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CN101998854A (zh) * | 2007-12-07 | 2011-03-30 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的制剂 |
| MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| JP2011522860A (ja) | 2008-06-10 | 2011-08-04 | ノバルティス アーゲー | 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体 |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
| EP2349263B1 (en) * | 2008-10-23 | 2014-04-23 | Vertex Pharmaceuticals Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
| US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| KR101123178B1 (ko) * | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| MX2012004792A (es) | 2009-10-22 | 2013-02-01 | Vertex Pharma | Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas. |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| SI2826776T1 (sl) | 2010-03-25 | 2021-02-26 | Vertex Pharmaceuticals Incorporated | Trdna disperzija amorfne oblike (R)-1(2,2-difluorobenzo(D)(1,3)dioksol-5-il)-N-(1-(2,3-dihidroksipropil) -6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1H-indol-5-il)- ciklopropankarboksamida |
| MX2012011655A (es) | 2010-04-07 | 2012-11-23 | Vertex Pharma | Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico. |
| JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| MX353408B (es) | 2010-04-22 | 2018-01-11 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| WO2012027247A2 (en) | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| AU2011346567A1 (en) | 2010-12-21 | 2013-07-25 | Novartis Ag | Bi-heteroaryl compounds as Vps34 inhibitors |
| WO2013030665A1 (en) | 2011-09-02 | 2013-03-07 | Purdue Pharma L.P. | Pyrimidines as sodium channel blockers |
| WO2013070961A1 (en) | 2011-11-08 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| DE202011108486U1 (de) | 2011-11-30 | 2012-01-16 | Walter Beck | Fensteranschlussleiste |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2867239A4 (en) | 2012-06-29 | 2015-12-23 | Lixte Biotechnology Inc | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES |
| AR092857A1 (es) | 2012-07-16 | 2015-05-06 | Vertex Pharma | Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas |
| EP2914248B2 (en) | 2012-11-02 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| RU2744460C2 (ru) | 2014-04-15 | 2021-03-09 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости |
| MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| JP7121794B2 (ja) | 2017-08-02 | 2022-08-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリジン化合物を調製するためのプロセス |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| EP3720849A2 (en) | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3575287A1 (en) * | 2018-05-31 | 2019-12-04 | Universiteit Leiden | Inhibitors of n-acylphosphatidylethanolamine phospholipase d (nape-pld) |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN116354937B (zh) * | 2021-12-27 | 2025-07-11 | 江苏恩华药业股份有限公司 | 吡啶(嘧啶)胺类衍生物及其应用 |
| CN117624135A (zh) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | 2-氮取代嘧啶类化合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9909135D0 (en) | 1999-04-22 | 1999-06-16 | Univ Wales Medicine | Cystic fibrosis medicaments |
| DE60112330T2 (de) * | 2000-12-15 | 2006-04-13 | Glaxo Group Ltd., Greenford | Pyrazolopyridinderivate |
| EP1430032A2 (en) * | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Substituted amides for the treatment of neurological disorders |
| US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| WO2004087679A1 (en) | 2003-04-01 | 2004-10-14 | Aponetics Ag | 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases |
| RU2006111093A (ru) * | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| WO2005113514A2 (en) * | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Substituted pyrimidines as inhibitors of bacterial type iii protein secretion systems |
-
2006
- 2006-05-22 JP JP2008513583A patent/JP5426878B2/ja not_active Expired - Fee Related
- 2006-05-22 CN CNA2006800258695A patent/CN101223146A/zh active Pending
- 2006-05-22 AT AT06770825T patent/ATE533749T1/de active
- 2006-05-22 AU AU2006251624A patent/AU2006251624A1/en not_active Abandoned
- 2006-05-22 US US11/438,636 patent/US8822451B2/en active Active
- 2006-05-22 EP EP06770825A patent/EP1891018B1/en not_active Not-in-force
- 2006-05-22 CA CA002609392A patent/CA2609392A1/en not_active Abandoned
- 2006-05-22 WO PCT/US2006/019712 patent/WO2006127588A2/en not_active Ceased
-
2012
- 2012-10-17 JP JP2012229668A patent/JP2013010800A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008542279A5 (https=) | ||
| RU2454405C2 (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| JP2011518219A5 (https=) | ||
| US9096571B2 (en) | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | |
| KR100581199B1 (ko) | 글리코겐 신타제 키나제 3의 억제제 | |
| RU2005136655A (ru) | Производные пиримидина, пригодные для лечения болезней, опосредованных сrth2 | |
| JP2006509748A5 (https=) | ||
| JP2013517283A5 (https=) | ||
| TWI455715B (zh) | ４－（４－氰基－２－硫基芳基）二氫嘧啶酮類及其用途 | |
| JP2019523266A5 (https=) | ||
| JP2004536814A5 (https=) | ||
| HRP20212000T1 (hr) | Aminotriazolopiridini kao inhibitori kinaze | |
| JP2007501264A5 (https=) | ||
| RU2003115612A (ru) | Производные амидоалкилпиперидинов и амидоалкилпиперазинов, пригодные для лечения нарушений нервной системы | |
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| JP2010536767A5 (https=) | ||
| JP2009526072A5 (https=) | ||
| JP2009524589A5 (ja) | 置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用 | |
| JP2008509910A5 (https=) | ||
| JP2004532227A5 (https=) | ||
| JP2013517273A5 (https=) | ||
| RU2017126199A (ru) | Биарильное производное в качестве агониста gpr120 | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| NZ588652A (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| CA2551529A1 (en) | Amide derivative and medicine |